7 AAC 145.400 - Covered outpatient drug payment rates and home infusion therapy drug rates
(a) In
addition to complying with the requirements of
7 AAC
105.220, and before submitting a claim for payment
from the department, a pharmacy provider shall bill any third-party
prescription drug plan in which the recipient is enrolled and that is in effect
on the date of service. After the pharmacy provider receives notification from
the third-party prescription drug plan of the amount, if any, that the
third-party prescription drug plan will pay, the pharmacy provider may submit a
claim for payment from the department for the remaining cost of service. The
department will pay the pharmacy provider the lesser of the difference between
the payment by the third-party prescription drug plan and the
department-calculated allowable payment, minus any recipient cost-sharing
amounts imposed under
AS
47.07.042 by the department or the remaining
patient liability amount, minus any recipient cost-sharing amounts imposed
under
AS
47.07.042 by the department. The department
will consider the payment to be payment in full.
(b) For a prescription of a covered
outpatient drug as described in
7 AAC
120.110(b), the department will pay
the provider for reasonable and necessary postage or freight shipping, not to
exceed $16, incurred in the delivery of the prescription from the dispensing
pharmacy to the recipient if pharmacy services are not available in the
recipient's community. If multiple prescriptions for covered outpatient drugs
are shipped in a single package, the postage or freight shipping costs must be
divided by the number of prescriptions for covered outpatient drugs shipped and
the partial postage amount is to be billed on each prescription claim.
(c) The department may establish a
state maximum allowable cost for a covered outpatient drug described in
7 AAC
120.110(b). The state maximum
allowable cost will be established by reviewing pricing sources, including the
wholesale acquisition cost, purchase invoices, or direct price for the covered
outpatient drug as identified in the First Data Bank National Drug Data
File (NDDF) Plus, taking into consideration the cost of the most
frequently dispensed drugs.
(d)
The department will maintain on its website, or on the website of the
department's designated contractor, a current listing of covered outpatient
drugs and their corresponding state maximum allowable costs.
(e) The payment for covered outpatient drugs
described in
7 AAC
120.110(b) is the lowest of the
following:
(1) the submitted covered
outpatient drug cost plus the dispensing fee set under
7 AAC
145.410;
(2) the federal upper limit established by
CMS plus the dispensing fee;
(3)
the estimated acquisition cost of the covered outpatient drug plus the
dispensing fee;
(4) the state
maximum allowable cost plus the dispensing fee.
(f) The department will pay for a vaccine
product at the rate established in 7 AAC 145.275(1).
(1) the submitted vaccine cost plus the
submitted vaccine administration fee under
7 AAC 145.410;
(2) the state maximum allowable
cost plus the vaccine administration fee;
(3) the federal upper limit established by
CMS plus the submitted vaccine administration fee;
(4) the estimated acquisition cost plus the
vaccine administration fee.
(g) The payment for brand names of
multiple-source drugs that are covered outpatient drugs described in
7 AAC
120.110(b) and that the prescriber
specifies in accordance with
42 C.F.R.
447.512, adopted by reference, is the lowest
of the following:
(1) the submitted covered
outpatient drug cost plus the dispensing fee set under
7 AAC 145.410;
(2) the estimated acquisition cost
of the covered outpatient drug plus the dispensing fee.
(h) For a specific covered outpatient drug
described in
7 AAC
120.110(b), a provider may not submit
a charge to the department in excess of the amount applicable to that drug
under
7 AAC
145.020 or the provider's usual and customary charge
for the covered outpatient drug. The usual and customary charge is the lowest
amount a provider charges to the general public and reflects all advertised
savings, discounts, special promotions, or other programs. The department will
pay the lesser of the calculated allowed amount under (e) - (o) of this section
less any cost-sharing amount under
7 AAC
105.610, the charged amount submitted under
7 AAC
145.020 less any cost-sharing amount under
7 AAC
105.610, or the provider's usual and customary charge
less any cost-sharing amount under
7 AAC
105.610.
(i) For a compounded prescription that
contains one or more covered outpatient drugs described in
7 AAC
120.110(b), the department will pay
the sum of the dispensing fee set under
7 AAC 145.410 and
the cost of each covered outpatient drug, with the cost of each covered
outpatient drug set at the lowest of the following:
(1) the submitted cost for that covered
outpatient drug;
(2) the federal
upper limit established by CMS for that covered outpatient drug;
(3) the state maximum allowable cost for that
covered outpatient drug;
(4) the
estimated acquisition cost for that covered outpatient drug.
(j) A provider that dispenses
covered outpatient drugs described in
7 AAC
120.110(b) in unit doses to a
recipient in a long-term care facility shall return unused covered outpatient
drugs to the pharmacy, and the claim will be adjusted.
(k) For covered outpatient drugs described in
7 AAC
120.110(b) and used as home infusion
therapy drugs for patients in a long-term care facility, the department will
pay a provider the sum of the dispensing fee set under
7 AAC 145.410 and
the cost of each covered outpatient drug, with the cost of each covered
outpatient drug set at the lowest of the following:
(1) the submitted cost for that covered
outpatient drug;
(2) the state
maximum allowable cost for that covered outpatient drug;
(3) the federal upper limit established by
CMS for that covered outpatient drug;
(4) the estimated acquisition cost for that
covered outpatient drug.
(l) For covered outpatient drugs described in
7 AAC
120.110(b) and used as home infusion
therapy drugs for patients outside a long-term care facility, the department
will pay a provider the sum of the covered outpatient drug costs without a
dispensing fee, with the cost of each covered outpatient drug set at the lowest
of the following:
(1) the submitted cost for
that covered outpatient drug;
(2)
the state maximum allowable cost for that covered outpatient drug;
(3) the federal upper limit established by
CMS for that covered outpatient drug;
(4) the estimated acquisition cost for that
covered outpatient drug.
(m) If a facility is a covered entity as
described in
42
U.S.C. 256 b (sec. 340B, Public Health
Service Act) and indicates to the United States Department of Health and Human
Services that it will use covered outpatient drugs purchased through the 340B
drug pricing program under
42
U.S.C. 256 b and 42 C.F.R. Part 10 to bill
Medicaid, the facility must notify the department and may not submit a charge
to Medicaid for more than the actual acquisition cost of the covered outpatient
drug and a dispensing fee calculated under
7 AAC 145.410. If
a covered entity as described in
42
U.S.C. 256 b notifies the United States
Department of Health and Human Services, Health Resources and Services
Administration, Office of Pharmacy Affairs of any changes in the entity's
enrollment or participation in the program, including that the entity's
pharmacy is not included under
42
U.S.C. 256 b, that the entity's pharmacy is
going to begin using covered outpatient drugs purchased through the 340B
program to bill Medicaid, or that the pharmacy is no longer going to use
covered outpatient drugs purchased through the 340B program to bill Medicaid,
the entity shall also notify the department. For covered outpatient drugs from
a facility indicating to the United States Department of Health and Human
Services that it will use covered outpatient drugs purchased through the 340B
drug pricing program to bill Medicaid, the department will pay the lesser of
the following:
(1) the submitted actual
acquisition covered outpatient drug cost plus the dispensing fee set under
7 AAC 145.410;
(2) the federal upper limit
established by CMS plus the dispensing fee;
(3) the estimated acquisition cost plus the
dispensing fee;
(4) the state
maximum allowable cost plus the dispensing fee.
(n) For purposes of (m) of this section,
actual acquisition covered outpatient drug cost is the unit cost that the
facility pays for a drug, after subtracting all discounts. A facility may
establish written protocols for establishing or calculating the facility's
actual acquisition drug cost based on a monthly, quarterly, or other average of
the facility's actual acquisition drug cost. A written protocol may not include
an inflation, mark-up, spread, or margin to be added to the facility's actual
purchase price after subtracting all discounts.
(o) If a facility purchases drugs through the
Federal Supply Schedule of the United States General Services Administration or
drug pricing program under
38
U.S.C. 8126, 42 U.S.C. 256 b, or
42 U.S.C.
1396r-8, other than through the 340B drug
pricing program under
42
U.S.C. 256 b and 42 C.F.R. Part 10, the
facility shall notify the department. The facility shall notify the department
of any changes in participation in purchasing drugs through the Federal Supply
Schedule or drug pricing program under
38
U.S.C. 8126, 42 U.S.C. 256 b, or
42 U.S.C.
1396r-8. For covered outpatient drugs from a
facility purchasing drugs through the Federal Supply Schedule or drug pricing
program under
38
U.S.C. 8126, 42 U.S.C. 256 b, or
42 U.S.C.
1396r-8 other than through the 340B drug
pricing program, the department will pay the lesser of the following:
(1) the submitted covered outpatient drug
cost plus the dispensing fee set under
7 AAC 145.410;
(2) the federal upper limit
established by CMS plus the dispensing fee;
(3) the wholesale acquisition cost of the
covered outpatient drug minus 15 percent plus the dispensing fee;
(4) the state maximum allowable cost plus the
dispensing fee.
(p) In
this section,
(1) "estimated acquisition
cost" means the wholesale acquisition cost plus one percent;
(2) "home infusion therapy"
(A) means drugs that require the use of a
laminar flow hood or clean room for the protection of either the product or
preparing personnel;
(B) includes
cancer chemotherapy drugs, intravenous antibiotics, and hyperalimentation
drugs;
(3) "wholesale
acquisition cost" means the manufacturer's list price for the drug to
wholesalers or direct purchasers in the United States, not including
prompt-payor other discounts, rebates, or reductions in price, for the most
recent month for which the information is available, as reported in wholesale
price guides or other publications of drug pricing data.
Notes
Authority:AS 47.05.010
AS 47.07.030
AS 47.07.040
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.